HealthcareOn the MoveM&ASupernus to acquire depression drugmaker SageJun. 16, 2025 7:27 AM ETSage Therapeutics, Inc. (SAGE) Stock, SUPN StockBIIBBy: Dulan Lokuwithana, SA News Editor2 CommentsPlay(1min) Supernus Pharmaceuticals (NASDAQ:SUPN) has agreed to acquire depression drugmaker Sage Therapeutics (NASDAQ:SAGE) for a total consideration of up to $795M, or $12 per share, in an all-cash deal, the companies announced on Monday. Shares of Supernus (NASDAQ:SUPN) traded flatRecommended For YouRelated StocksSymbolLast Price% ChgSUPNSUPN--SAGESAGE--1D5D1M6M1Y5Y10YCompareTrending AnalysisTrending News
